Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences (Nasdaq: TLSA) announced on December 15, 2025 that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of Tiziana common stock in the open market.

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced on December 15, 2025 that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of Tiziana common stock in the open market.

Following this transaction, the CEO's total purchased shares amount to 357,848. The purchase was executed on the open market and reflects an insider buy by the company's chief executive.

Positive

• CEO purchased 163,400 shares in open market
• CEO total purchased shares now 357,848

Negative

• None.

Argus Dec 15 session

-10.67% close to close Open Argus

Details

News Market Reaction – TLSA

On Dec 15, the day this news came out, TLSA closed 10.67% below the previous close.

Data tracked by StockTitan Argus for the Dec 15 session.

Market Context

On Dec 15, the day this news came out, the stock closed 10.7% below the previous close. A negative r...

Analysis

On Dec 15, the day this news came out, the stock closed 10.7% below the previous close. A negative reaction despite seemingly constructive news would fit prior patterns where some announcements, particularly without immediate financial or clinical impact, saw selling pressure. Historical events showed that conference-related or strategic updates sometimes preceded declines. In such situations, investors often focused on funding visibility, upcoming trial milestones, and overall sector risk appetite as elements that could either deepen or eventually stabilize the move.

Key Figures

CEO share purchase: 163,400 shares Total CEO purchased shares: 357,848 shares

CEO share purchase

163,400 shares

Open-market purchase by Chief Executive Officer

Total CEO purchased shares

357,848 shares

Cumulative purchased Tiziana common stock held by CEO

Historical Context

5 past events · Latest: Dec 12

5 events

1. Dec 12

   Clinical trial update

   24h Move

   +3.5%

   Phase 2 Alzheimer’s trial enrollment and first dosing timing for intranasal foralumab.

2. Dec 02

   Strategic spinout plan

   24h Move

   +0.0%

   Plan to spin out IL-6 asset TZLS-501 into a separate listed company.

3. Nov 25

   Clinical trial update

   24h Move

   +5.2%

   ALS Phase 2 trial for intranasal foralumab accepted into Healey ALS MyMatch Program.

4. Nov 13

   Conference presentation

   24h Move

   -7.3%

   Jefferies conference corporate overview highlighting pipeline and clinical milestones.

5. Oct 29

   Conference participation

   24h Move

   -3.1%

   BIO-Europe 2025 presentation and partnering focus on intranasal foralumab programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immunomodulation therapies, intranasal foralumab, monoclonal antibody, anti-CD3

4 terms

immunomodulation therapies medical

"a biotechnology company developing breakthrough immunomodulation therapies with its lead development"

Treatments that change how the immune system behaves to prevent or fight disease, either by calming an overactive response or boosting a weak one — like adjusting a thermostat to keep temperature in a safe range. They matter to investors because they can create big market opportunities if proven effective, but also carry high development, clinical trial and regulatory risks that can strongly affect a company’s future value.

intranasal foralumab medical

"with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody"

Intranasal foralumab is an experimental antibody medication given as a spray or drops into the nose that aims to change how the immune system behaves rather than attack a virus directly. Investors care because results from trials, safety findings, and regulatory decisions determine whether this approach can become a marketed therapy, affecting a company’s future sales, development costs and competitive position — similar to betting on a new product that could reshape a company’s revenue stream.

monoclonal antibody medical

"intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

anti-CD3 medical

"lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today"

An anti‑CD3 is an antibody drug that binds to the CD3 protein on T cells, the immune system’s frontline soldiers, to change how those cells behave. Think of it like attaching a remote control to specific immune cells to dial their activity up, down or redirect them; for investors, anti‑CD3 therapies signal a drug class with significant promise in autoimmune diseases, transplant protection and certain cancer strategies, but also carry clinical, regulatory and safety risks that strongly influence valuation and trial outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tiziana (TLSA) announce on December 15, 2025 about insider buying?

Tiziana announced its CEO, Ivor Elrifi, purchased 163,400 shares in the open market, bringing his total purchased shares to 357,848.

How many Tiziana (TLSA) shares did CEO Ivor Elrifi own after the December 15, 2025 purchase?

After the purchase the CEO's purchased shares totalled 357,848.

Was the CEO purchase of Tiziana (TLSA) shares a private transaction or open market trade?

The purchase was executed in the open market.

Does the December 15, 2025 filing for Tiziana (TLSA) state the purchase price per share?

No price per share was disclosed; the announcement only states the number of shares purchased.

Could the CEO purchase on December 15, 2025 affect Tiziana (TLSA) stock price?

Insider buys can signal executive confidence; the announcement reports the 163,400 share open-market purchase but does not project price impact.

Where can investors find the official disclosure of Ivor Elrifi's Tiziana (TLSA) share purchase?

Investors can review the company's public disclosures and Nasdaq filings for official transaction details and timing.